5 recruiting, 3 active not recruiting, 3 completed, 2 not yet recruiting. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Recruiting 5, Active not recruiting 3, Completed 3, Not yet recruiting 2 |
Follow PM 01183: new trials by email Literature Review of PM 01183 trials Research Report on PM 01183
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer ZL-1310 in combination with Atezolizumab or Durvalumab, Carboplatin/Etoposide in Combination with Atezolizumab followed by maintenance Atezolizumab with Lurbinectedin, Carboplatin/Etoposide or Cistplatin/Etoposide in Combination with Durvalumab induction followed by Durvalumab maintenance - Extensive-Stage Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Zai Lab (Shanghai) Co., Ltd. | 530 | 2026-12-31 | 2026-08-31 |
| A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303) Ris-Rez, Atezolizumab, Etoposide - Lung Neoplasm | Phase 3 | Not yet recruiting | GlaxoSmithKline | 700 | 2026-12-25 | 2026-11-18 |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) BL-M14D1 and Atezolizumab, Carboplatin+ Etoposide + Atezolizumab followed by Atezolizumab and Lurbinectedin - Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer | Phase 3 | Recruiting | SystImmune Inc. | 550 | 2026-08-04 | 2026-11-12 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer ABBV-706, Topotecan, Lurbinectedin - Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 531 | 2026-07-02 | 2026-09-23 |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only) - Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Recruiting | Gilead Sciences | 695 | 2025-04-04 | 2026-10-20 |
| Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC Lurbinectedin, Irinotecan, Topotecan - Relapsed Small Cell Lung Cancer | Phase 3 | Recruiting | Luye Pharma Group Ltd. | 180 | 2024-09-14 | 2024-12-12 |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Ifinatamab deruxtecan, Topotecan, Amrubicin - Small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 540 | 2024-05-21 | 2026-08-06 |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) Lurbinectedin, Doxorubicin - Leiomyosarcoma | Phase 3 | Active not recruiting | PharmaMar | 469 | 2023-09-21 | 2026-06-18 |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer Tarlatamab, Lurbinectedin, Topotecan - Small Cell Lung Cancer (SCLC) | Phase 3 | Active not recruiting | Amgen | 509 | 2023-05-31 | 2026-01-05 |
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) Irinotecan, Lurbinectedin, Topotecan - Relapsed Small Cell Lung Cancer | Phase 3 | Completed | PharmaMar | 705 | 2022-07-22 | 2026-10-21 |
| A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer Atezolizumab, Lurbinectedin, Carboplatin - Small-Cell Lung Cancer | Phase 3 | Active not recruiting | Hoffmann-La Roche | 660 | 2021-11-18 | 2026-09-09 |
| Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer Lurbinectedin (PM01183), Doxorubicin (DOX), Cyclophosphamide (CTX) - Small-cell Lung Cancer | Phase 3 | Completed | PharmaMar | 613 | 2016-08-30 | 2021-10-28 |
| Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients Lurbinectedin (PM01183), Pegylated liposomal doxorubicin (PLD), Topotecan - Ovarian Cancer | Phase 3 | Completed | PharmaMar | 442 | 2015-05-01 | 2020-04-03 |
Small Cell Lung Carcinoma (10) · Lung Neoplasms (2) · Neoplasms (2) · Carcinoma, Small Cell (1) · Leiomyosarcoma (1) · Ovarian Neoplasms (1)
PharmaMar (4) · AbbVie (1) · Amgen (1) · Daiichi Sankyo (1) · Gilead Sciences (1) · GlaxoSmithKline (1) · Hoffmann-La Roche (1) · Luye Pharma Group Ltd. (1) · SystImmune Inc. (1) · Zai Lab (Shanghai) Co., Ltd. (1)
United States (10) · Germany (9) · Spain (9) · Belgium (8) · France (8) · Italy (8) · Poland (8) · Greece (7) · Hungary (7) · Austria (6) · Brazil (6) · Canada (6) · South Korea (6) · United Kingdom (6) · Australia (5)
Junliang Cai, MD (1) · Ying Chen, Doctor (1)
PMID 34521554, PMID 36252599, PMID 37407274, PMID 39530627, PMID 39932221, PMID 40473449, PMID 40963055, PMID 41055143, PMID 42377743
2023 (2), 2025 (1)